Magnesium Sulfate and Postoperative Hypercoagulability in Laparoscopic Gynecological Surgeries

Launched by MARIANNA MAVROMATI · Nov 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how magnesium sulfate, a common medication, affects the blood's tendency to clot after laparoscopic gynecological surgeries, which are minimally invasive surgeries performed on women. The goal is to find out if magnesium sulfate can help prevent excessive blood clotting after these surgeries, a condition known as hypercoagulability. The study will involve women aged 18 and older who are classified as ASA I or II, meaning they are generally healthy or have mild health issues. Participants must also be taking preventive blood-thinning medications before and after their surgery.

If you or someone you know is considering participating in this trial, you can expect to be part of a double-blind study, meaning neither you nor the researchers will know who is receiving magnesium sulfate and who is getting a placebo (a non-active substance). The study is currently recruiting participants, and it's important to note that certain health conditions, like severe obesity, pregnancy, or serious medical issues, would exclude someone from participating. This trial aims to improve the safety and care of women undergoing these types of surgeries by understanding how magnesium sulfate may help manage blood clotting.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • ASA I and II patients
• • Laparoscopic gynecological surgeries
• • age \>18 years
• • Patients receiving prophylactic anticoagulant therapy 12 hours before surgery based on the Caprini score
• • Patients receiving prophylactic anticoagulant therapy 12 hours postoperatively based on the Caprini score.
• Exclusion Criteria:
• • ASA ≥ III
• • age \<18 years
• • BMI \>40 kg/m²
• • Pregnancy
• • Known hematologic disorders
• • Liver/kidney/cardiovascular disease
• • Severe anemia (6,5- 7,9 g/dl)
• • Inability or refusal to provide informed consent